Wells Fargo & Company MN Has $19.03 Million Position in MEDNAX Inc (MD)

Wells Fargo & Company MN trimmed its stake in shares of MEDNAX Inc (NYSE:MD) by 54.0% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 407,732 shares of the company’s stock after selling 479,223 shares during the period. Wells Fargo & Company MN owned about 0.44% of MEDNAX worth $19,025,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of the stock. Oregon Public Employees Retirement Fund boosted its position in MEDNAX by 3.4% during the second quarter. Oregon Public Employees Retirement Fund now owns 36,599 shares of the company’s stock worth $1,584,000 after purchasing an additional 1,196 shares in the last quarter. Janus Henderson Group PLC lifted its position in shares of MEDNAX by 0.4% in the second quarter. Janus Henderson Group PLC now owns 316,826 shares of the company’s stock valued at $13,714,000 after acquiring an additional 1,300 shares in the last quarter. SG Americas Securities LLC lifted its position in shares of MEDNAX by 8.8% in the second quarter. SG Americas Securities LLC now owns 17,350 shares of the company’s stock valued at $751,000 after acquiring an additional 1,398 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of MEDNAX by 3.6% in the third quarter. Sterling Capital Management LLC now owns 43,981 shares of the company’s stock valued at $2,052,000 after acquiring an additional 1,510 shares in the last quarter. Finally, GHP Investment Advisors Inc. lifted its position in shares of MEDNAX by 19.8% in the third quarter. GHP Investment Advisors Inc. now owns 9,775 shares of the company’s stock valued at $456,000 after acquiring an additional 1,615 shares in the last quarter. 98.51% of the stock is currently owned by hedge funds and other institutional investors.

Several research firms have recently weighed in on MD. Credit Suisse Group decreased their target price on MEDNAX from $55.00 to $50.00 and set an “outperform” rating on the stock in a research report on Tuesday, November 6th. UBS Group began coverage on MEDNAX in a research report on Friday, November 16th. They issued a “sell” rating and a $37.00 target price on the stock. Robert W. Baird decreased their target price on MEDNAX from $48.00 to $40.00 and set a “neutral” rating on the stock in a research report on Friday, November 2nd. Bank of America upgraded MEDNAX from an “underperform” rating to a “neutral” rating and decreased their target price for the company from $60.00 to $50.00 in a research report on Tuesday, September 18th. Finally, BMO Capital Markets decreased their target price on MEDNAX from $48.00 to $43.00 and set a “market perform” rating on the stock in a research report on Friday, November 2nd. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the stock. MEDNAX presently has a consensus rating of “Hold” and a consensus target price of $51.20.

Shares of MEDNAX stock opened at $40.20 on Friday. MEDNAX Inc has a one year low of $37.26 and a one year high of $63.04. The company has a market cap of $3.59 billion, a P/E ratio of 11.52, a P/E/G ratio of 1.07 and a beta of 0.33. The company has a current ratio of 1.43, a quick ratio of 1.43 and a debt-to-equity ratio of 0.67.

MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, November 1st. The company reported $0.94 EPS for the quarter, missing the Zacks’ consensus estimate of $0.97 by ($0.03). MEDNAX had a return on equity of 10.45% and a net margin of 9.50%. The company had revenue of $896.60 million for the quarter, compared to analysts’ expectations of $908.15 million. During the same quarter in the previous year, the business posted $0.87 EPS. The business’s quarterly revenue was up 3.2% compared to the same quarter last year. On average, research analysts predict that MEDNAX Inc will post 3.57 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Wells Fargo & Company MN Has $19.03 Million Position in MEDNAX Inc (MD)” was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of international copyright & trademark laws. The legal version of this piece of content can be accessed at https://www.com-unik.info/2018/12/02/wells-fargo-company-mn-has-19-03-million-position-in-mednax-inc-md.html.

MEDNAX Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

See Also: Swap

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit